Cardiology Conference-CVC 2026

Transcatheter Aortic Valve Replacement, or TAVR, is a minimally invasive treatment intended to address severe aortic stenosis, a disease in which the aortic valve narrows, impeding blood flow from the heart to the body. TAVR has transformed valve therapy, particularly for patients who are at high or intermediate risk for open-heart surgery, by offering a safe and effective alternative.

The process is the implantation of an artificial collapsible valve through a catheter, usually via the femoral artery, and its deployment inside the failing native valve. The method decreases recovery time, reduces surgical trauma, and enables quicker return to normal activity than traditional SAVR.

Patient selection is essential to ensure TAVR success. Candidates are comprehensively evaluated through echocardiography, CT scans, and risk assessment for procedural complications. The heart team, which includes interventional cardiologists, cardiac surgeons, and imaging experts, makes the optimal approach and device selection for each patient.

Results of TAVR are excellent, demonstrating dramatic symptom, functional status, and quality-of-life improvement. Complications are unusual but can comprise vascular injury, conduction disturbances, or paravalvular leak, which are successfully treated with modern interventional methods.

With ongoing advancements in device technology and procedural skill, TAVR has found its way to lower-risk patients, thus becoming one of the most critical developments in structural heart interventions. The procedure is the epitome of minimally invasive cardiology, which provides safe, effective, and patient-focused care for patients with aortic valve disease.